CTRI/2012/06/002720已完成4 期
Clinical evaluation of safety and immunogenicity of an indigenously developed purified chick embryo cell rabies vaccine when administered intradermally in animal bite cases
I0 个研究点目标入组 70 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects with low risk Category II and Category III exposures.
- •Subjects willing to give signed informed consent.
- •Subjects willing to give blood samples on recommended days.
- •Subjects available for minimum of 6 months follow-up.
- •Dog/Cat domesticated, available for 10 days observation, apparently healthy, provoked bite, wound washed with soap and water and consulting for vaccination within 48 hours of exposure.
排除标准
- •Pregnancy & lactation.
- •Subjects who had received any type of rabies vaccine/immunoglobulin in the past.
- •Subjects with very severe bite wounds.
- •Subjects with chronic illness or cancers.
- •Subjects on steroids or any other immunosuppressant or is known to be HIV positive.
- •Subjects planning for surgery in the next 3 month
- •Subjects on concomitant antimalarials.
- •Subjects with history of allergy to any ingredient of the vaccine.
- •Participation in another clinical trial in the past 3 months.
- •Past history of chronic alcoholic abuse.
研究者
相似试验
Unknown
3 期
A clinical trial to study immunogenicity and safety of Purified Chick Embryo Cell Culture Rabies Vaccine administered intradermallyCTRI/2010/091/000509Cadila Healthcare Ltd36
已完成
3 期
Safety and immunogenicity of rabies vaccines in animal bite cases administered using new one week intradermal regimeCTRI/2012/12/003230Department of Community Medicine Kempegowda Institute of Medical Sciences KIMS80
尚未招募
4 期
Assessment of the protection offered by single dose of COVID-19 vaccines in individuals previously affected with COVID-19CTRI/2021/10/037099Indian Council of Medical research ICMR
尚未招募
3 期
Phase III study of the Cuban vaccine candidate VCN7-T in patients from 1 to 18 years of age at risk of pneumococcal disease in HavanaPneumococcal diseasesVCN7-TPneumococcal InfectionsStreptococcal InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsRPCEC00000432Finlay Vaccine Institute (FVI)
进行中（未招募）
不适用
Safety, clinical tolerability and immune activity of increasing doses of the investigational medicinal product gpASIT+TM administered under the skin to patients suffering from hay fever.Treatment of seasonal grass pollen rhinoconjunctivitis.MedDRA version: 15.1Level: LLTClassification code 10019170Term: Hay feverSystem Organ Class: 100000004870EUCTR2013-000056-18-DEBioTech Tools S.A.